Axsome Therapeutics (AXSM) is joining with the Alzheimer’s disease advocacy community to raise awareness of the growing impact of Alzheimer’s disease in the United States and the importance of brain health during this year’s Alzheimer’s & Brain Awareness Month. During Alzheimer’s & Brain Awareness Month, Axsome is working with advocacy and patient communities to raise awareness and share resources, in addition to participating at scientific and medical conferences throughout the year.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AXSM:
- Optimistic Buy Rating for Axsome Therapeutics Amid Promising Developments and Strategic Initiatives
- Axsome Therapeutics supports Migraine, Headache Awareness Month
- Strong Growth Potential and Market Penetration Drive Buy Rating for Axsome Therapeutics
- Axsome Therapeutics price target lowered to $186 from $193 at RBC Capital
- Axsome Therapeutics: Buy Rating Affirmed Amid Promising Pipeline Developments and Strategic Focus